SRNE - Sorrento Therapeutics Is Still A Buy April, 11 2021 12:06 PM Sorrento Therapeutics Inc. Sorrento Therapeutics recently announced the acquisition of ACEA Therapeutics. ACEA's acquisition brings to Sorrento the late clinical-stage Abivertinib. The company received a supplemental new drug application approval from FDA for its lidocaine topical system ZTlido. For further details see: Sorrento Therapeutics Is Still A Buy